April 10, 2010: Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary a tentative approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Forest Laboratories, Inc.’s Namenda 5 mg and 10 mg tablets.
These generic Memantine tablets are equivalent to Forest Laboratories, Inc’s Namenda® tablets and includes two strengths: 5 mg and 10 mg. These strengths of Memantine have a combined annual sale of approximately $1.2 billion in the US.
Memantine tablets are indicated for the treatment of moderate to severe Alzheimer’s Disease... [PDF] Sun Pharmaceutical Industries' Press Release -
Blog Archive
-
▼
2010
(50)
-
▼
April
(8)
- Octapharma : Trial on Intravenous Immunoglobulin (...
- Siena Biotech : Roche exercises option on compound...
- Avid Radiopharmaceuticals, Cardinal Health : Miles...
- Signum Biosciences : Alzheimer’s Drug Discovery Fo...
- Sun Pharma : USFDA tentative approval for generic ...
- GE Healthcare : positive Phase 2 data with fluteme...
- BELLUS Health : launch of NRM8499 Phase I clinical...
- Takeda & Janssen : About Agreement Reached to Co-m...
-
▼
April
(8)
Monday, April 19, 2010
Sun Pharma : USFDA tentative approval for generic Namenda® tablets
Libellés :
Forest Laboratories,
Sun Pharmaceutical Industries